Abstract：
OBJECTIVE: To report a newborn patient with gastrointestinal (GIS) perforation after intravitreal ranibizumab (RBZ) treatment.
METHODS: The patient was born at 31 gestational week and hospitalized with the diagnosis of small for gestational age and prematurity. In the follow up he underwent GIS surgery due to necrotizing enterocolitis (NEC) and was diagnosed with retinopathy of prematurity (ROP). At 43 weeks of postmenstrual age, he developed intestinal perforation after 12 h of the second low-dose RBZ injection. According to our knowledge, this is the first report of GIS perforation due to low-dose intravitreal RBZ treatment in an infant with severe ROP.
CONCLUSIONS: The risk of GIS perforation should be taken into consideration during the application of intravitreal vascular endothelial growth factor antagonist agents, especially in newborns with previous GIS surgery and a history of NEC, and these patients should be carefully monitored for GIS complications.
METHODS: The patient was born at 31 gestational week and hospitalized with the diagnosis of small for gestational age and prematurity. In the follow up he underwent GIS surgery due to necrotizing enterocolitis (NEC) and was diagnosed with retinopathy of prematurity (ROP). At 43 weeks of postmenstrual age, he developed intestinal perforation after 12 h of the second low-dose RBZ injection. According to our knowledge, this is the first report of GIS perforation due to low-dose intravitreal RBZ treatment in an infant with severe ROP.
CONCLUSIONS: The risk of GIS perforation should be taken into consideration during the application of intravitreal vascular endothelial growth factor antagonist agents, especially in newborns with previous GIS surgery and a history of NEC, and these patients should be carefully monitored for GIS complications.
摘要：
目的：报告1例接受玻璃体内雷珠单抗（RBZ）治疗后发生胃肠道（GIS）穿孔的新生儿。
方法：患者出生31孕周，住院诊断为小于胎龄和早产。在随访中，由于坏死性小肠结肠炎（NEC），他接受了GIS手术，并被诊断为早产儿视网膜病（ROP）。在月经后的43周龄，他在第二次低剂量RBZ注射12小时后出现肠穿孔。据我们所知,这是首次报道严重ROP婴儿因玻璃体内低剂量RBZ治疗导致的GIS穿孔.
结论：在玻璃体内应用血管内皮生长因子拮抗剂时，应考虑GIS穿孔的风险，特别是在有过GIS手术和NEC病史的新生儿中，这些患者应仔细监测GIS并发症。
方法：患者出生31孕周，住院诊断为小于胎龄和早产。在随访中，由于坏死性小肠结肠炎（NEC），他接受了GIS手术，并被诊断为早产儿视网膜病（ROP）。在月经后的43周龄，他在第二次低剂量RBZ注射12小时后出现肠穿孔。据我们所知,这是首次报道严重ROP婴儿因玻璃体内低剂量RBZ治疗导致的GIS穿孔.
结论：在玻璃体内应用血管内皮生长因子拮抗剂时，应考虑GIS穿孔的风险，特别是在有过GIS手术和NEC病史的新生儿中，这些患者应仔细监测GIS并发症。
